创新药板块回调，创新药ETF国泰（517110）盘中跌超2%，机构表示集采影响或已出清

Group 1 - The State Council emphasizes the need to strengthen the evaluation of drug and consumable procurement policies, aiming for a more standardized and institutionalized approach to procurement work [1] - The scope of drug procurement in China has expanded significantly since 2018, now including various fields such as chemical injectable drugs, traditional Chinese medicine, and IVD consumables, with plans to include biosimilars and chemiluminescence in the future [1] - The rapid advancement of procurement has led to a clearing of price reduction impacts in certain segments, resulting in a turning point for the performance of related companies [1] Group 2 - China's innovative drugs are entering a stage of realization of results, with significant R&D progress that is not affected by trade frictions, positioning them as a key investment theme in the pharmaceutical sector for 2025 [1] - The ongoing acceleration of procurement in different pharmaceutical fields is expected to lead to new growth opportunities in the future [1] Group 3 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug (RMB) Index (931409), which includes listed companies involved in the R&D, production, and sales of innovative drugs, reflecting the overall performance of the innovative drug sector in the A-share market [2] - The index is designed to represent companies with significant R&D investment characteristics and growth potential within the pharmaceutical and biotechnology industry [2]